One of the latest developments in the pharmaceutical arena is South Korean biopharmaceutical company, Celltrion Healthcare’s expansion of access to YUFLYMA (adalimumab-aaty). On October 5, Celltrion Healthcare announced a new contract with Ventegra, a renowned U.S.-based Medical Benefits Manager (MBM) known for successfully replacing traditional Pharmacy Benefit Managers with its Pharmacy Services Administration (PSA) model.
Ventegra, via its groundbreaking PSA model, administers pharmacy benefits, offering a more flexible and consumer-tailored approach to healthcare services. The new contract with Celltrion represents a significant advent in the availability and dissemination of YUFLYMA. This substance is a biosimilar-using molecule that demonstrates a high degree of similarity to an already FDA-approved biological product—Humira (adalimumab). FDA approved YUFLYMA in February 2021 for the treatment of eight inflammatory diseases.
However, initial access to the drug has been limited. This new agreement with Ventegra has the potential to substantially increase patient reach for the treatment, as Ventegra’s established network with multidisciplinary healthcare providers across the U.S. allows for a wider distribution of YUFLYMA.
Potentially, this collaboration could be a defining moment for Celltrion Healthcare, as they seek to secure a substantial share of the global pharmaceutical market, specifically commendable in the high-potential segment of biological product manufacturing. While it is early to estimate the full impact of this collaboration, it is undeniably an important step in the firm’s growth strategy, offering an effective treatment to a larger patient populace.
For more information and details about Celltrion’s YUFLYMA and its collaboration with Ventegra, you can read the full announcement here. Stay up-to-date with the developments in the pharmaceutical industry, particularly regarding the entry and expansion of biosimilar medicines like YUFLYMA into the market.